APPLICATION
ANDA077833
TYPE
ANDA
ORIGINAL APPROVAL
2007-03-30
LATEST ACTION
2024-08-29
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued
Products
NADOLOL AND BENDROFLUMETHIAZIDEDiscontinued
BENDROFLUMETHIAZIDE 5MG, NADOLOL 40MG · TABLET · ORAL
NADOLOL AND BENDROFLUMETHIAZIDEDiscontinued
BENDROFLUMETHIAZIDE 5MG, NADOLOL 80MG · TABLET · ORAL
Approval history
2024-08-29Labeling · Supplement 16 · standardAP
2016-04-26Labeling · Supplement 8 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.